- The new analyses of the P-III BREEZE-AD5 trial and an extended safety analysis across multiple trials for Olumiant (2mg, qd) vs PBO in patients with AD showed improvements in the severity and extent of AD and patient outcomes, other key symptoms, and QoL as early as 1wks.
- Olumiant has also evaluated in patients with BSA >50% at baseline showed improvements in the severity and extent of AD and achieved 75% improvement in EASI 75. Safety was consistent with the overall safety population across the clinical program
- The extended safety analysis across 8 studies adetermines the safety profile of Olumiant and showed no increases in rates for AEs, SAEs, or serious infections with therapy
Click here to read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly